Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer

• Publication date

  2001-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(20011215)92:12<2975::AID-CNCR10113>3.0.CO;2-KPMID 11753974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histological Typing of Prostate Tumours

  2002cited by this paper
• Molecular Cloning of the Human Kallikrein 15 Gene (KLK15)

  2001cited by this paper
• Development of a dual monoclonal antibody immunoassay for total human kallikrein 2.

  2001cited by this paper
• Differentially Expressed Genes in Two LNCaP Prostate Cancer Cell Lines Reflecting Changes during Prostate Cancer Progression

  2000cited by this paper
• Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.

  2000cited by this paper
• A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer.

  2000cited by this paper
• Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids.

  1999cited by this paper
• Antiangiogenic activity of prostate-specific antigen.

  1999cited by this paper
• Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2.

  1999cited by this paper
• Quantitation of erbB-2 gene copy number in breast cancer by an improved polymerase chain reaction (PCR) technique, competitively differential PCR

  1999cited by this paper
• Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen.

  1999cited by this paper
• Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.

  1999cited by this paper
• Androgen receptor gene amplification increases tissue PSA protein expression in hormone‐refractory prostate carcinoma

  1999cited by this paper
• Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.

  1999cited by this paper
• Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.

  1999cited by this paper
• Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis.

  1999cited by this paper
• The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.

  1999cited by this paper
• Genetic alterations in hormone-refractory recurrent prostate carcinomas.

  1998cited by this paper
• Mouse 17 beta-hydroxysteroid dehydrogenase type 2 mRNA is predominantly expressed in hepatocytes and in surface epithelial cells of the gastrointestinal and urinary tracts.

  1998cited by this paper
• Androgen-sensitive human prostate cancer cells, LNCaP, produce both N-terminally mature and truncated prostate-specific antigen isoforms.

  1998cited by this paper
• The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma

  1998cited by this paper
• Human glandular kallikrein, hK2, shows arginine‐restricted specificity and forms complexes with plasma protease inhibitors

  1998cited by this paper
• Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes.

  1998cited by this paper
• alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein.

  1998cited by this paper
• Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum.

  1998cited by this paper
• Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

  1997cited by this paper
• Nonprostatic sources of prostate-specific antigen.

  1997cited by this paper
• Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.

  1997cited by this paper
• Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels.

  1997cited by this paper
• Differential expression patterns of the PEA3 group transcription factors through murine embryonic development

  1997cited by this paper
• Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein.

  1997cited by this paper
• Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum.

  1996cited by this paper
• Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation.

  1996cited by this paper
• Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization.

  1996cited by this paper
• Prostate‐Specific antigen expression by various tumors

  1995cited by this paper
• Serum free prostate specific antigen: Isoenzymes in benign hyperplasia and cancer of the prostate

  1995cited by this paper
• Expression of Active, Secreted Human Prostate-specific Antigen by Recombinant Baculovirus-infected Insect Cells on a Pilot-scale

  1995cited by this paper
• Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

  1994cited by this paper
• Protease inhibitors: role and potential therapeutic use in human cancer.

  1994cited by this paper
• Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth.

  1993cited by this paper
• Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern‐blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies

  1993cited by this paper
• A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

  1991cited by this paper
• Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin.

  1991cited by this paper
• 19 – SAMPLE PREPARATION FROM PARAFFIN-EMBEDDED TISSUES

  1990cited by this paper
• Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.

  1990cited by this paper
• Time-resolved immunofluorometric assay of human prostate-specific antigen.

  1990cited by this paper
• Expression of the gene coding for human prostate‐specific antigen and related hGK‐1 in benign and malignant tumors of the human prostate

  1990cited by this paper
• cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes.

  1989cited by this paper
• Primary Structure of a Human Glandular Kallikrein Gene

  1987cited by this paper
• High-affinity monoclonal antibodies specific for human prostatic acid phosphatase.

  1987cited by this paper
• A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

  1985cited by this paper
• The role of proteinases in cellular invasiveness.

  1983cited by this paper
• The role of proteinase in cellular invasiveness

  1983cited by this paper
• Latent carcinoma of the prostate.

  1954cited by this paper

• Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

  2025cites this paper
• EPA Modulates KLK Genes via miR-378: A Potential Therapy in Prostate Cancer

  2022cites this paper
• Dietary phosphorus intake and serum prostate-specific antigen in non-prostate cancer American adults: A secondary analysis of the National Health and Nutrition Examination Survey (NHANES), 2003-2010.

  2020cites this paper
• Lectin PCL inhibits the Warburg effect of PC3 cells by combining with EGFR and inhibiting HK2.

  2017cites this paper
• Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies

  2016cites this paper
• p,p'-Dichlorodiphenyltrichloroethane (p,p'-DDT) and p,p'-dichlorodiphenyldichloroethylene (p,p'-DDE) repress prostate specific antigen levels in human prostate cancer cell lines.

  2015cites this paper
• Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.

  2015cites this paper
• Human Kallikrein-2, PSA and Free-PSA for Discrimination of Syrian Prostate Cancer from Benign Disease

  2015cites this paper
• Altered glycosylation in prostate cancer.

  2015cites this paper
• Targeting kallikrein-related peptidases in prostate cancer

  2014cites this paper
• Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients

  2014cites this paper
• Quantitative Analysis of Novel Prostate Cancer Markers in Tissue

  2014influential citation
• Molecular Identification of the Indolent Versus Lethal Tumor

  2013cites this paper
• Detection of α-Methylacyl-Coenzyme-A Racemase Transcripts in Blood and Urine Samples of Prostate Cancer Patients

  2012cites this paper
• Image cytometry analysis of circulating tumor cells.

  2011cites this paper
• Identification of new urine biomarkers for the detection of prostate cancer

  2011cites this paper
• Translational perspectives on MSMB and CRISP3 expression and regulation in prostate cancer

  2011cites this paper
• Genome-wide association studies of cancer predisposition.

  2010cites this paper
• Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers

  2009cites this paper
• A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells.

  2009cites this paper
• Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs)

  2008cites this paper
• Development of peptides specifically modulating the activity of KLK2 and KLK3

  2008cites this paper
• Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.

  2008cites this paper
• Kallikrein-related peptidase 4 activation of protease-activated receptor family members and association with prostate cancer

  2008cites this paper
• Matrix Degradation in Prostate Cancer

  2008cites this paper
• Prostate-specific antigen and prostate cancer: prediction, detection and monitoring

  2008cites this paper
• Metastasis of prostate cancer

  2007cites this paper
• Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.

  2007influential citation
• hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.

  2007cites this paper
• Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.

  2006cites this paper
• Differential expression of the KLK 2 and KLK 3 genes in peripheral blood and tissues of patients with prostate cancer

  2006cites this paper
• Differential expression of the KLK2 and KLK3 genes in peripheral blood and tissues of patients with prostate cancer

  2006cites this paper
• Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.

  2005cites this paper
• DETECTION OF PROSTATE SPECIFIC mRNAs IN CIRCULATION AND IN PROSTATIC TISSUE

  2005cites this paper
• Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue

  2005influential citation
• Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA)

  2004cites this paper
• The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers

  2004cites this paper
• Targeting gene therapy for prostate cancer.

  2004cites this paper
• Quantitative analysis of kallikrein 15 gene expression in prostate tissue.

  2003cites this paper
• 16 Role of prostate-specific glandular kallikrein 2 in prostate carcinoma

  2002cites this paper
• Novel human prostate-specific cDNA: molecular cloning, expression, and immunobiology of the recombinant protein.

  2002cites this paper
• Renal medicine and renal transplantation.

  2000cites this paper